TechnipFMC plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TechnipFMC plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.93B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $9.08B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $7.82B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $6.70B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $6.40B | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $3.43B | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | $3.34B | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | $3.16B | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | $3.13B | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | $3.73B | Mar 5, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.68B | Apr 2, 2018 |
| FY2017 | Sep 30, 2017 | $4.14B | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | $3.85B | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | $3.39B | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $2.05B | Apr 2, 2018 |
| FY2017 | Sep 30, 2016 | $2.38B | Apr 2, 2018 |
| FY2017 | Jun 30, 2016 | $2.37B | Apr 2, 2018 |
| FY2017 | Mar 31, 2016 | $2.41B | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $11.47B | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $963.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $842.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $56.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($107.20M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $13.30M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($39.30M) | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | ($3.90M) | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | $11.70M | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | ($3.26B) | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | ($2.41B) | Mar 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.16B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $658.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $375.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $183.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($3.24B) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($2.11B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($532.70M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $1.35B | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $766.10M | Mar 11, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $73.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $69.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $67.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $78.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $75.30M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $149.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $189.20M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $212.90M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $105.40M | Mar 11, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $705.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $667.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $675.90M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $616.80M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $644.90M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $724.10M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $795.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.14B | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $1.06B | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $572.60M | Mar 11, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $961.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $693.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $352.10M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $781.30M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $656.90M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $848.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($185.40M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $210.70M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $493.80M | Mar 11, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $317.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $281.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $225.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $157.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $191.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $256.10M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $412.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $368.10M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $255.70M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $312.90M | Mar 11, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.12B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $9.87B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $9.66B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $9.44B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $10.02B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $19.69B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $23.52B | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $24.78B | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $28.26B | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $18.68B | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.71B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.73B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $6.48B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.17B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.60B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $15.43B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $15.79B | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $14.36B | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $14.85B | Mar 11, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.36B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.09B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.14B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.24B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $3.40B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $4.15B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $7.66B | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $10.36B | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $13.39B | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $5.06B | Apr 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.51B | Mar 5, 2021 |
| FY2021 | Dec 31, 2019 | $3.13B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $7.61B | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $8.93B | Mar 3, 2020 |
| FY2019 | Dec 31, 2016 | $3.72B | Mar 3, 2020 |
| FY2018 | Dec 31, 2015 | $3.79B | Mar 11, 2019 |
| FY2017 | Dec 31, 2014 | $4.11B | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.76B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($4.31B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($4.99B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($5.01B) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($4.90B) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($4.92B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.56B) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $1.07B | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $3.45B | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $3.40B | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.16B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $951.70M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.06B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.33B | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $1.27B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $1.56B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $5.54B | Mar 5, 2021 |
| FY2020 | Dec 31, 2017 | $6.74B | Mar 5, 2021 |
| FY2019 | Dec 31, 2016 | $6.27B | Mar 3, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $430.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $885.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.07B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.37B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.00B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $3.46B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $4.48B | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $4.19B | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $3.86B | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $2.55B | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | (7) | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | (5) | Mar 5, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | (7) | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | (5) | Mar 5, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 400.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 423.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 432.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 442.20M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 450.70M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 449.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 447.10M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | 450.50M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 465.10M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | 118.90M | Apr 2, 2018 |